Atuka’s lead scientists have dedicated their careers to furthering our understanding of Parkinson’s disease, advancing novel therapeutics, and alleviating the burden of those suffering from neurological disorders.

Founded by Dr. Jonathan Brotchie in 2003, Atuka has been involved in the preclinical evaluation of more than 200 potential therapeutics, predominantly in Parkinson’s disease, of which more than 20 have progressed to clinical trials—a level of experience without equal in our field globally. Our lead scientists have collectively published more than 300 peer-reviewed, highly-cited papers, and individually possess h-indices ranging from 25 to 70.

With offices and facilities in Toronto, Suzhou, and Shanghai, Atuka’s team is diverse both in background and expertise, bringing to every one of our partner engagements a spirit of close collaboration, along with a commitment to the highest ethical standards in scientific research.